LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Regeneron Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

609.16 -0.48

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

606.89

Макс.

613.89

Ключевые показатели

By Trading Economics

Доход

-117M

727M

Продажи

-279M

3.6B

P/E

Средняя по отрасли

14.925

49.052

Прибыль на акцию

9.47

Дивидендная доходность

0.56

Рентабельность продаж

20.17

Сотрудники

15,343

EBITDA

-234M

967M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+35.08% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

0.56%

2.36%

Следующий отчет о доходах

31 июл. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-14B

64B

Предыдущая цена открытия

609.64

Предыдущая цена закрытия

609.16

Новостные настроения

By Acuity

56%

44%

275 / 342 Рейтинг в Healthcare

Regeneron Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

О компании Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat